

SEQUENCE LISTING

<110> LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES
BIOTECHNOLOGIES (LFB)

<110> INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
(INSERM)

<120> THERAPEUTIC PRODUCTS WITH ENHANCED ABILITY TO IMMUNOMODULATE CELL
FUNCTIONS

<130> D21018

<150> EP 03/290 834

<151> 2003-04-03

<160> 6

<170> PatentIn version 3.2

<210> 1

<211> 21

<212> DNA

<213> artificial

<220>

<223> Amplimer sense

<400> 1

gcagctcccc caaaggctgt g

21

<210> 2

<211> 21

<212> DNA

<213> artificial

<220>

<223> Amplimer antisense

<400> 2

ttggacagtg atggtcacag g

21

<210> 3

<211> 33

<212> DNA

<213> artificial

<220>

<223> Amplimer sense

<400> 3

tggatgaatt ccctattaag tgatggtgat gtt

33

<210> 4

<211> 23

<212> DNA

<213> artificial

<220>

<223> Amplimer antisense

<400> 4

atcggatccc gactgaagat ctc

23

<210> 5

<211> 990

<212> DNA

<213> human

<220>

<223> Constant region of the heavy chain of LFB1/LFB2 antibody.

<400> 5

gcctccacca agggcccatc ggtcttcccc ctggcacccct cctccaagag cacctctggg 60
ggcacagcgg ccctgggctg cctggtcaag gactacttcc cccgaaccgtt gacggtgtcg 120
tggaaacttag ggcgcctgac cagcggcgtg cacaccccttcc cggctgtctt acagtccctca 180
ggactctact ccctcagcag cgtggtgacc gtgccttcca gcagcttggg caccaggacc 240
tacatctgca acgtgaatca caagcccagc aacaccaagg tggacaagaa agttgagccc 300
aaatcttggt acaaaaactca cacatgccc ccgtgcccag cacctgaact cctggggggga 360
ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatacttc ccggacccct 420
gaggtcacat gcgtgggtgg ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg 480
tacgtggacg gcgtggaggt gcataatgcc aagacaaaagc cgcgggagga gcagttacaac 540
agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag 600
gagttacaatgtc gcaagggtctc caacaaagcc ctcccagccc ccattcgagaa aaccatctcc 660
aaagccaaag ggcagccccc agaaccacag gtgtacaccc tgcccccattt ccggatgtag 720
ctgaccaaga accaggttcag cctgacctgc ctggtcaaaag gcttcttatcc cagcgacatc 780
gccgtggagt gggagagcaa tggcagccg gagaacaact acaagaccac gcctccctgt 840
ctggactccg acggctctt ctccctctac agcaagctca ccgtggacaa gagcagggtgg 900
cagcaggggaa acgtcttctc atgtccctgt atgcattgagg ctctgcacaa ccactacacg 960
cagaagagcc tctccctgtc tccgggtaaa 990

<210> 6

<211> 990

<212> DNA

<213> human

<220>

<223> Constant region of the heavy chain of LFB3 antibody.

<400> 6

gcctccacca agggcccatc ggtcttcccc ctggcacccct cctccaagag cacctctggg 60
ggcacagcgg ccctgggctg cctggtcaag gactacttcc cccgaaccgtt gacggtgtcg 120
tggaaacttag ggcgcctgac cagcggcgtg cacaccccttcc cggctgtctt acagtccctca 180
ggactctact ccctcagcag cgtggtgacc gtgccttcca gcagcttggg caccaggacc 240
tacatctgca acgtgaatca caagcccagc aacaccaagg tggacaagag agttgagccc 300
aaatcttggt acaaaaactca cacatgccc ccgtgcccag cacctgaact cctggggggga 360
ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatacttc ccggacccct 420
gaggtcacat gcgtgggtgg ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg 480
tacgtggacg gcgtggaggt gcataatgcc aagacaaaagc cgcgggagga gcagttacaac 540
agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag 600
gagttacaatgtc gcaagggtctc caacaaagcc ctcccagccc ccattcgagaa aaccatctcc 660
aaagccaaag ggcagccccc agaaccacag gtgtacaccc tgcccccattt ccggatgtag 720
atgaccaaga accaggttcag cctgacctgc ctggtcaaaag gcttcttatcc cagcgacatc 780

gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccg 840
ctggactccg acggctcctt ctccctctat agcaagctca ccgtggacaa gagcagggtgg 900
cagcagggga acgttttc atgctccgtg atgcattgagg ctctgcacaa ccactacacg 960
cagaagagcc tctccctgtc cccggtaaa 990